Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Amplification of c‐erbB2 oncogene: A major prognostic indicator in uterine serous papillary carcinoma

Open access
Santin, Alessandro D., Bellone, Stefania, Van Stedum, Sue, Bushen, Wendy, Palmieri, Michela, Siegel, Eric R., De Las Casas, Luis E., Roman, Juan J., Burnett, Alexander, Pecorelli, Sergio · 2005 · Cancer

Abstract

BACKGROUND: Overexpression of the epidermal growth factor type II receptor HER‐2/neu has been associated with resistance to chemotherapy and poor survival in several human tumors. In the current study, the authors have determined the frequency and clinical significance of HER‐2/neu gene amplification in uterine serous papillary endometrial carcinoma (USPC), a highly aggressive variant of endometrial carcinoma. METHODS: Fluorescence in situ hybridization (FISH) assay was used to analyze gene amplification in paraffin blocks from 30 women harboring Stage IA–IV USPC treated at the University of Arkansas for Medical Sciences (Little Rock, AR) from 1997 to 2004. Chromosome 17 polysomy status by FISH was also assessed in all specimens. USPC patient survival in relation to HER‐2/neu gene amplification was analyzed using Kaplan–Meier curves in conjunction with the log‐rank test. RESULTS: Amplification of the HER‐2/neu gene by FISH was observed in 14 of the 30 (47%) cases. Heterogeneity was noted in 4 of 14 cases in the amplification of the HER‐2/neu gene within the same tumor samples with pockets of amplified tumor cells amidst nonamplified tumor cells. Patients with USPC harboring tumors with HER‐2/neu gene amplification had a significantly shorter survival time from diagnosis to disease‐related death when compared with FISH‐negative patients (P = 0.0008). African‐American (AA) patients were found to have a poorer prognosis compared with Caucasian (C) women (P = 0.01) and to harbor USPC with significantly higher levels of HER‐2/neu gene amplification (P = 0.02). CONCLUSIONS: HER‐2/neu gene amplification in USPC was found to be an important prognostic indicator for poor outcome that occurs more frequently in AA when compared with C patients. Determination of HER‐2/neu gene amplification may guide clinical management of patients with USPC and may have important implications for the implementation of novel treatment strategies. Cancer 2005. © 2005 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.21308

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 168

Metadata

Authors
Santin, A. D., Bellone, S., Van Stedum, S., Bushen, W., Palmieri, M., Siegel, E. R., De Las Casas, L. E., Roman, J. J., Burnett, A., & Pecorelli, S.
Venue
Cancer
Publisher
Wiley
Published
2005-09-17
Volume
104
Issue
7
Pages
1391-1397
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2039241242
Cited by
168
References
3
FWCI
1.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amplification of c‐erbB2 oncogene: A major prognostic indicator in uterine serous papillary carcinoma. https://app.cochat.ai/papers/10.1002/cncr.21308
The paper
Santin, A. D., Bellone, S., Van Stedum, S., Bushen, W., Palmieri, M., Siegel, E. R., De Las Casas, L. E., Roman, J. J., Burnett, A., & Pecorelli, S. (2005). Amplification of c‐erbB2 oncogene: A major prognostic indicator in uterine serous papillary carcinoma. Cancer. https://doi.org/10.1002/cncr.21308

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.